Brainstorm Cell Therapeutics Names Setboun Chief Operating Officer

David Setboun has been appointed executive vice president and chief operating officer of Brainstorm Cell Therapeutics (NASDAQ: [[ticker:BCLI]]). He is joining New York-based Brainstorm from Life Biosciences, where he was vice president of corporate development, strategy and business. Setboun’s experience also includes positions at Biogen (NASDAQ: [[ticker:BIIB]]), AstraZeneca (NYSE: [[ticker:AZN]]), and Eli Lilly (NYSE: [[ticker:LLY]]). Brainstorm’s lead program,  NurOwn, is in Phase 3 testing in amyotrophic lateral sclerosis and in Phase 2 testing in progressive multiple sclerosis.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan